Early Immune Changes Support Signet Ring Cell Dormancy in CDH1-Driven Hereditary Diffuse Gastric Carcinogenesis.


Journal

Molecular cancer research : MCR
ISSN: 1557-3125
Titre abrégé: Mol Cancer Res
Pays: United States
ID NLM: 101150042

Informations de publication

Date de publication:
01 12 2023
Historique:
received: 24 02 2023
revised: 07 08 2023
accepted: 11 09 2023
medline: 4 12 2023
pubmed: 14 9 2023
entrez: 14 9 2023
Statut: ppublish

Résumé

Stage IA gastric adenocarcinoma, characterized by foci of intramucosal signet ring cells (SRC), is found in nearly all asymptomatic patients with germline pathogenic CDH1 variants and hereditary diffuse gastric cancer syndrome (HDGC). The molecular steps involved in initiating malignant transformation and promoting SRC dormancy in HDGC are unknown. Here, whole-exome bulk RNA sequencing (RNA-seq) of SRCs and adjacent non-SRC epithelium (NEP) was performed on laser-capture microdissected (LCM) regions of interest found in risk-reducing total gastrectomy specimens from patients with HDGC (Clinicaltrials.gov ID: NCT03030404). In total, 20 patients (6 male, 14 female) with confirmed HDGC were identified. Analysis of differentially expressed genes (DEG) demonstrated upregulation of certain individual EMT and proliferation genes. However, no oncogenic pathways were found to be upregulated in SRCs. Rather, SRC regions had significant enrichment in pathways involved in T-cell signaling. CIBERSORTx predicted significant increases in the presence of regulatory T cells (Treg) specific to SRC regions. IHC confirmed an increase in FOXP3+ cells in SRC foci, as well as elevations in CD4+ T cells and HLA-DR staining. In summary, the tumor immune microenvironment is microscopically inseparable from stage IA gastric SRCs using a granular isolation technique. An elevation in CD4+ T cells within SRC regions correlates with clinically observed SRC dormancy, while Treg upregulation represents a potential immune escape mechanism. Characterization of the tumor-immune microenvironment in HDGC underscores the potential for the immune system to shape the transcriptional profile of the earliest tumors, which suggests immune-directed therapy as a potential cancer interception strategy in diffuse-type gastric cancer.

Identifiants

pubmed: 37707375
pii: 729068
doi: 10.1158/1541-7786.MCR-23-0122
doi:

Substances chimiques

Cadherins 0
CDH1 protein, human 0
Antigens, CD 0

Banques de données

ClinicalTrials.gov
['NCT03030404']

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Intramural Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1356-1365

Subventions

Organisme : National Institutes of Health (NIH)
ID : R01-ES015339
Organisme : National Institutes of Health (NIH)
ID : R35-ES028374
Organisme : National Institutes of Health (NIH)
ID : R01-CA226898

Informations de copyright

©2023 American Association for Cancer Research.

Auteurs

Benjamin L Green (BL)

Surgical Oncology Program, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.

Lauren A Gamble (LA)

Surgical Oncology Program, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.

Laurence P Diggs (LP)

Surgical Oncology Program, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.

Darryl Nousome (D)

Biomedical Informatics and Data Science, Frederick National Laboratory for Cancer Research, NCI, NIH, Frederick, Maryland.

Jesse C Patterson (JC)

Koch Institute for Integrative Cancer Research, MIT Center for Precision Cancer Medicine, Departments of Biology and Bioengineering, Massachusetts Institute of Technology, Cambridge, Maryland.

Brian A Joughin (BA)

Koch Institute for Integrative Cancer Research, MIT Center for Precision Cancer Medicine, Departments of Biology and Bioengineering, Massachusetts Institute of Technology, Cambridge, Maryland.

Billel Gasmi (B)

Surgery Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.

Stephanie C Lux (SC)

Surgical Oncology Program, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.

Sarah G Samaranayake (SG)

Surgical Oncology Program, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.

Markku Miettinen (M)

Laboratory of Pathology, NCI, NIH, Bethesda, Maryland.

Martha Quezado (M)

Laboratory of Pathology, NCI, NIH, Bethesda, Maryland.

Jonathan M Hernandez (JM)

Surgical Oncology Program, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.

Michael B Yaffe (MB)

Surgical Oncology Program, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
Koch Institute for Integrative Cancer Research, MIT Center for Precision Cancer Medicine, Departments of Biology and Bioengineering, Massachusetts Institute of Technology, Cambridge, Maryland.

Jeremy L Davis (JL)

Surgical Oncology Program, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH